| Social Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > News and Society > Energy > Wylfa B, Anglesey Nuclear Build Prospects |
|
Social Articles - Wylfa B, Anglesey Nuclear Build Prospects
Wylfa B is the name given to the putative new nuclear power station at Wylfa on Anglesey in the UK. The present Wylfa Magnox Power Station is set to close in 2010, followed by defuelling up to about 2012. According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product There will then follow a long period of site clean-up and demolition as part of the planned decommissioning process. Whether Wylfa B goes ahead depends very much on the long term energy strategy adopted b ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in y the UK government. Against a backdrop of rising global energy demand and increasing concerns about greenhouse gas emissions, the need for action is urgent. Clearly, the recent comments in Parliament by lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. listair Darling, UK Trade and Industry Secretary, that the government intends to give the private sector an opportunity to invest in a new nuclear build programme is very encouraging. The new White Paper e here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe ntitled “Meeting the Energy Challenge” sees nuclear energy making a significant contribution to the energy mix for the UK going forward. At the moment nuclear power contributes about 20 per cent to UK elec d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro tricity generation, but this will fall drastically to less than 7 per cent by 2023 with the closure and decommissioning of the aging Magnox and AGR reactors. Only the PWR reactor at Sizewell B in Suffolk w ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc uld remain after this time if no further plants are built. This represents a huge loss of low carbon generated electricity capacity and if the government wants to keep on track for its own emission reducti easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi on targets, new build seems an urgent priority. Policymakers face a huge dilemma as the UK will face a cut of over a third in its generating capacity over the next decade as a result of retiring nuclear an nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically d coal plants, the latter to comply with EU cleaner emissions regulations. While the government energy white paper covers issues including energy efficiency and boosting electricity sourced from renewables and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ to 15 per cent by 2015, it is clear that nuclear build grabs the agenda. Along with this white paper there is a new consultation on nuclear power following a High Court challenge by Greenpeace in respect o ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi f the earlier Energy Review. That process was considered to have been inadequate because it did not take sufficient account of the issues of waste and economics. Together with security of supply and capac ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a ity concerns, the other issue of concern is achieving a low carbon source for the UK’s baseload electricity needs. Remember that coal and gas still contribute over 70 per cent of electricity generating capa dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod ity in Britain. Mr Darling, in his Commons statement, said new nuclear build was most likely to be on existing sites such as Wylfa on Anglesey. This way there is likely to be less resistance to such major cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin infrastructure projects which have proved controversial in the past. With the national grid transmission infrastructure and turbines already in place at the Anglesey site, Wylfa B faces fewer hurdles than tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen a new location. The new fast track approach to planning announced in a recent White Paper will also reduce the lead-time from design to completion. Public inquiries will only be able to challenge a project t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel on local planning issues, such as transport, environmental and socio-economic impact. So once a strategic national decision is, for example, taken on nuclear energy, no objection could be made to a project ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust on the grounds that it was new nuclear build. And now both EDF Energy and E.ON have already moved ahead on submitting their pre-licensing applications for reactor designs to the Nuclear Installation Inspe y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products ctorate. Representatives from EDF Energy and E.ON have also expressed interest, and visited, the proposed Wylfa B location on Anglesey as a candidate for nuclear build. Successive opinion polls on the isl . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de nd suggest very strong support in favour of a new nuclear power station on Anglesey. And Anglesey County Council and local politicians are also supportive of the proposed Wylfa B, knowing how vital it would elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip be to the local economy. So with the UK government anxious to press ahead to tackle the looming energy gap and go for low carbon electricity generation, prospects on Anglesey look bright for a new Wylfa B tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:How to Use the Internet Safely to Find Service Providers Part 2 Keyword Selection - The Foundation of Your Website 10m Brits Looking To Remortgage
|